Anavex Life Sciences Corp (AVXL)

[Doc328]

I believe you are right.

Most conferences of this size will have 3-6 scientific sessions going on concurrently, with different emphasis. Each session is usually chaired by 2 scientists. They give a very brief 1 minute preview of what's to be presented. Then each talk is usually 10-15 minutes (12 is typical, 7 minutes is very short) with the last 1-2 minutes of each slot for 1-2 questions. After all the talks in that scientific session are complete, the speakers come back on stage and there is open Q/A for another 15-20 minutes. So from the schedule it looks like Sabbagh will speak Sunday 4:27 to 4:39 and probably will get a couple questions at the end (5:15 to 5:40). The total session with presentations is 90 minutes I think his talk, will have a good sized audience. Generally the P2 and P3 presentations have more people attending than the esoteric talks and will be held in a bigger room to accommodate. Its good to see the ADCS-ADL finally presented. As already inferred, based on its absence from prior PR's, this endpoint with LSM/MMRM statistics had a wide miss (p=.23). Hopefully the slides will add even more color than this and not just re-present the September 2023 PR --i.e. let's see the final n's; 30 vs 50 mg; S1R WT vs Q2P.
https://alz.confex.com/alz/2024/meetingapp.cgi/Paper/90729

Dr. Jin's talk Monday July 28 at 8:20 is actually being presented by a colleague so he will not be on stage. From the abstract, A273 data may not be presented. Looks like they are mostly talking about composite endpoints and using the combined z-test stats. Given the abstract, looks like they will be commenting on donanemab. It is slated for 10 minutes
https://alz.confex.com/alz/2024/meetingapp.cgi/Session/12905

the Annovis PR does not match the agenda and both have the same time. Looks like the whole session is 45 minutes but the talk is only 7 minutes plus maybe a couple questions after the last talk.
https://alz.confex.com/alz/2024/meetingapp.cgi/Session/13177